Replies to post #42664 on Ayala Pharmaceuticals Inc (ADXS)

[longx]

I would suggest that the best option for Advaxis to increase its cash position without dilution is to merge with Versatis. Versartis's only drug, Somavaratan, recently failed in Phase 3 clinical trial and currently hires Cowen to assist in evaluating possible strategic transactions to for maximize it's cash asset of over $118M as reported in its latest 10-Q filing

Hope that Lombardo could see this as an opportunity:
https://www.versartis.com/
https://finance.yahoo.com/quote/VSAR/profile?p=VSAR
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12372187&RcvdDate=11/9/2017&CoName=VERSARTIS%2C%20INC.&FormType=10-Q&View=html